SurroMed's technology and research capabilities can be utilized to add value along the entire drug discovery and development process from pre-clinical testing to Phase IV post-approval studies. Major areas of application include:

• Target discovery and clinical validation of candidate targets
• Increased understanding of drug effects
• Improved animal models of disease
• More rapid determination of efficacy, safety, and optimal dosing regimens
• Patient stratification by disease sub-type and response to therapy

SurroMed currently has research studies ongoing in rheumatoid arthritis, osteoarthritis, TNF-inhibition, respiratory disease, Alzheimer's disease, multiple sclerosis, and diabetes. Our biomarker discovery studies focus on disease areas with large patient populations, unmet clinical needs, and significant challenges in drug development.

In addition, we are also applying our biomarker discovery capabilities to discovery of biomarkers in pre-clinical studies.